Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
Healthcare
$15.49 -1.25%
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
52W Low $6.67High $28.00
Volume 0.79M
Average 0.83M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$94.69M
FY 2025 · Annual
Investing Cash Flow
-$247.01M
FY 2025 · Annual
Financing Cash Flow
$360.77M
FY 2025 · Annual
+1318.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (22.96M) | (51.51M) | (75.52M) | (69.63M) | (127.41M) |
| Depreciation & Amortization | 15K | 68K | 96K | 282K | 26K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (6.51M) | 7.76M | 9.8M | (11.17M) | (8.2M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 609K | 1.37M | (164K) | (2.17M) | 361K |
| Other Working Capital | (7.12M) | 6.39M | 9.96M | (9M) | (8.56M) |
| Other Non-Cash Items | 2.06M | 4.57M | 8.85M | 9.32M | 40.89M |
| Operating Cash Flow | (27.4M) | (39.12M) | (56.78M) | (71.2M) | (94.69M) |
| Capital Expenditures | (181K) | (195K) | (142K) | 0 | (196K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (113.25M) | (147.62M) | (123.98M) | (19.68M) | (261.19M) |
| Sales of Investments | 0 | 154.74M | 136M | 75.71M | 14.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (31K) |
| Investing Cash Flow | (113.43M) | 6.93M | 11.88M | 56.03M | (247.01M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.46M | 396K | 46M | 25.43M | 360.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 156K |
| Financing Cash Flow | 190.46M | 396K | 46M | 25.43M | 360.77M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (52.82M) |
| Net Change in Cash | 49.62M | (31.8M) | 1.09M | 10.26M | 54.69M |
| Free Cash Flow | (27.58M) | (39.32M) | (56.92M) | (71.2M) | (94.89M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$127.4M
+ D&A$26.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$8.2M
+ Other Non-Cash$40.9M
= Operating Cash Flow-$94.7M
- Capex-$196.0K
= Free Cash Flow-$94.9M
Analysis
FY2025 free cash flow is -$94.9M. FCF conversion is 74.5% of net income. Operating cash flow was -$94.7M, with capex of -$196.0K. The largest bridge item is Other Non-Cash at $40.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Oct 28, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 | |
| 424B5 | 424B5 filing | Jun 3, 2026 |
Does JBIO generate free cash flow?
Jade Biosciences, Inc. (JBIO) generated -$94.89M of free cash flow in fiscal 2025.
How much operating cash flow does JBIO produce?
Operating cash flow was -$94.69M, before capital expenditures of $196,000.00.
Continue the stock analysis
Jump to another research area for this company.